Meeting
2018 ASCO Annual Meeting
Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
Authors
R Donald Harvey
Winship Cancer Institute of Emory University, Atlanta, GA
R Donald Harvey , Jonathan L. Kaufman , Leonard T. Heffner , Craig C. Hofmeister , Mahdav V. Dhodapkar , Sagar Lonial , Ajay K. Nooka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8046)
DOI
10.1200/JCO.2018.36.15_suppl.8046
Abstract #
8046
Poster Bd #
55
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).
First Author: Paul G. Richardson
Poster
2012 ASCO Annual Meeting
Impact of t (11;14) on the outcome of autologous hematopoietic cell transplantation (Auto-HCT) in multiple myeloma.
First Author: Koji Sasaki
Poster
2024 ASCO Annual Meeting
Effect of dose-adjusted melphalan on MRD-negativity to full dose melphalan in patients with multiple myeloma post-autologous stem cell transplant.
First Author: Jeries Kort
Poster
2023 ASCO Annual Meeting
Association between excess body mass index trajectory and change in monoclonal protein level in patients diagnosed with monoclonal gammopathy of undetermined significance.
First Author: Lawrence Liu